Renal Replacement Therapy - The good and the bad
|
|
- Cuthbert Small
- 6 years ago
- Views:
Transcription
1 Renal Replacement Therapy - The good and the bad Introduction Prevalence of Chronic kidney disease in Asia is rising as screening becomes more widespread. Glomerulonephritis as a cause of CKD is more common in Asia than in the Western world, perhaps because of infections and overcrowding. It is estimated that over 90% of patients with ESRD in South Asia die within months of diagnosis because they cannot afford treatment.the age-adjusted incidence of ESRD of India is estimated at 229 per million. Renal replacement therapy, which is the treatment of ESRD, constitutes Hemodialysis, Peritoneal dialysis and renal transplantation. Hemodialysis is the most common form of RRT in Asia, followed by peritoneal dialysis and renal transplantation. Ideally, when patients begin renal replacement therapy (RRT), they should meet the following conditions: firstly, they should not require hospitalization for the management of untreated acute or chronic complications of uremia; secondly, they should have a thorough understanding of the different treatment options; and thirdly, they should have a functioning, permanent access for the dialysis therapy of their choice.
2 Hemodialysis vs Peritoneal dialysis Dialysis modalities include hemodialysis, either in a dialysis center or at home, or peritoneal dialysis, including chronic ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). The percentage of patients undergoing hemodialysis far surpasses that being maintained on peritoneal dialysis. Based on the 2009 United States Renal Data System (USRDS) report, 94 and 6 percent began hemodialysis and peritoneal dialysis in the United States, respectively. Approximately 11 percent of dialysis patients worldwide are treated with peritoneal dialysis, with the relative proportion increasing in developing, but not developed countries Approximately 2.5 percent of patients with end-stage renal disease (ESRD) received a renal transplant as the initial treatment for their ESRD. Hemodialysis is generally more expensive than peritoneal dialysis. In 2006, Medicare expenditures for hemodialysis were $71,889 per patient per year, compared with $53,327 for those on peritoneal dialysis The selection of dialysis modality is influenced by a number of considerations such as availability and convenience, comorbid conditions, socioeconomic and dialysis-center factors, the patient's home situation, the method of physician reimbursement, and the ability to tolerate volume shifts. Patients generally like to have a choice of modalities. As an example, in the Netherlands study cited above, in which, among 738 eligible patients, only 38 agreed to be randomly assigned to a specific therapy, 50 percent of patients chose peritoneal dialysis Among some patients, it may be optimal to utilize both hemodialysis and peritoneal dialysis in a way that provides the advantages of each modality, but without the disadvantages. An optimal strategy, for example, may be an integrated-care approach in which incident dialysis patients initially undergo peritoneal dialysis, with transfer to hemodialysis once complications ensue with peritoneal dialysis. This is based in part on the hypothesis that, principally via its ability to preserve residual renal function, peritoneal dialysis provides significant benefits as an initial modality. Other benefits may include preservation of vascular access and perhaps better survival during the first few years of dialysis A large number of studies, practically all retrospective and observational, have been performed concerning the relative effect upon mortality of peritoneal dialysis versus incenter hemodialysis. The results have been conflicting, with hemodialysis reportedly having no difference, a relative benefit, or a relative adverse effect upon survival, compared with peritoneal dialysis. Reasons for these variable results include selection bias, flawed study design, differences in mortality effects with time from initiation of dialysis, differences in comorbid diseases, and other factors. Multiple studies have found that peritoneal dialysis may provide relative short-term survival benefits, but comparable or decreased survival after one to two years. Analysis of data provided by the United States Renal Data Systems (USRDS) also suggested a survival benefit associated with peritoneal dialysis during the first few years on dialysis, but which was lost over time. Patients on peritoneal dialysis had a slight overall survival
3 advantage, compared with those on hemodialysis during the first three years of therapy, but, at five years, survival was equal at 34 percent. The time after dialysis initiation at which the relative survival benefit associated with peritoneal dialysis is lost and survival comparisons start to favor hemodialysis depends on multiple variables, including the cause of ESRD, vintage (ie, the year patient started renal replacement therapy), gender, country of treatment, and presence or absence of comorbidities. As an example, the survival advantage conferred by peritoneal dialysis is not as robust if the primary case of ESRD is diabetes, the patient is older, or the patient has comorbidities. The presence of heart failure may also attenuate the early survival benefit associated with peritoneal dialysis. Although one study found one- and two-year survivals of 90 and 64 percent among peritoneal dialysis patients with severe systolic dysfunction, a subsequent study found poorer survival among new dialysis patients with heart failure who were initially treated with peritoneal dialysis, compared with hemodialysis. ACUTE COMPLICATIONS DURING HEMODIALYSIS: 1. Hypotension 25 to 55 percent of treatments 2. Cramps 5 to 20 percent
4 3. Nausea and vomiting 5 to 15 percent 4. Headache 5 percent 5. Chest pain 2 to 5 percent 6. Back pain 2 to 5 percent 7. Itching 5 percent 8. Fever and chills <1 percent 9. Hemolysis 10. Arrhythmias 11. Air embolism 12. Access issues Renal replacement therapy in acute kidney injury : Recovery of renal function and effect of hemodialysis membrane Dialysis may be required in patients with severe acute renal failure. Mortality in such patients is often associated with infection or bleeding. Since these problems can be exacerbated by uremia, it has been suggested that dialysis begun before evidence of overt uremia may lead to improved survival. This issue is complicated by evidence that dialysis may delay the recovery of renal function. Before discussing dialysis in acute renal failure, an overview of general issues in non-dialytic management of patients with established acute renal failure is indicated. The basic goals for the management of established acute renal failure are the maintenance of fluid and electrolyte balance, avoidance of nephrotoxic medications, adequate nutrition, treatment of infections, correction of reversible prerenal (eg, hypovolemia) and postrenal factors, close monitoring, and proper dosing of medications. There is a theoretical concern that dialysis might have detrimental effects on renal function. Three factors that may be important in this regard include a reduction in urine output; induction of hypotension; and complement activation resulting from a blood-dialysis membrane interaction. A reduction or cessation of the urine output results in both removal of excess volume and of urea. Urea may be a surrogate marker of other substances that are removed by dialysis which stimulate urine output. Hypotension is a common complication of hemodialysis. This may be a particular problem in recovery of renal function in a patient who has acute tubular necrosis (ATN). Whereas normal kidneys vasodilate in the presence of ischemia as part of the autoregulatory response to maintain renal blood flow and glomerular filtration rate near the baseline level, autoregulation is impaired in ATN, resulting in recurrent ischemic tubular injury, thereby delaying the restoration of function. Complement activation during the blood-dialyzer interaction with cuprophane membranes, but not more compatible membranes, can lead to neutrophilic infiltration into the kidney (and other tissues) and prolonged acute kidney injury. We favor the routine use of biocompatible dialysis membranes among patients with acute kidney injury. Membranes can be of low or high flux. High flux membranes can enhance removal of putative toxins and improve outcome, but may also allow the back transport (from dialysate to blood) of potentially harmful water-borne molecules.
5 Having the purest dialysate water possible should be a goal when using these more porous membranes to utilize their positive attributes and to minimize their potential risks. If the water used is high quality, we suggest that high flux biocompatible dialysis membranes be used in patients with acute kidney injury. If the water system is not of high quality, low flux biocompatible dialysis membranes should be used. Continuous renal replacement therapies Continuous renal replacement therapies (CRRTs) involve either dialysis (diffusion-based solute removal) or filtration (convection-based solute and water removal) treatments that operate in a continuous mode. Variations of CRRT might run 12 to 14 hours, especially during daytime periods of full staffing. This regimen has become more prevalent in Europe and has been called "go slow dialysis." Other variations of this technique are discussed below and probably should be called hybrid therapies because they are a merging of intermittent and continuous duration. The longer duration of CRRT makes it quite different from conventional intermittent hemodialysis (HD), in which each treatment lasts four to six hours or less. The major advantage of continuous therapy is the slower rate of solute or fluid removal per unit of time. Thus, CRRT is generally better tolerated than conventional therapy since many of the complications of intermittent HD are related to the rapid rate of solute and fluid loss. Artificial kidneys If an implantable device was to mimic the function of a native kidney it would need to operate continuously to remove solutes. The device would not necessarily need to be functionally flexible; that is, its capacity to remove water and solutes would not need to be able to adapt to day-to-day variations (as a native kidney can). Regular dialysis techniques are effective despite not having this adaptive capacity. The device would need to be wearable or implantable, lightweight, safe, and reliable. Nanotechnology, the science of developing functional machine systems on the scale of nanometers, could help in the design of membranes that are more selective than polymer membranes; that is, a membrane could be designed that filters in a manner analogous to that of the glomerulus. Other filters placed in series with this membrane could separate waste compounds from substances to be retained and returned to the circulation.
6 Tissue engineering and stem-cell techniques The aim of tissue engineering is to repair dysfunctional organs by using human tissue. Approaches to the repair and (re)construction of kidneys include the integration of new nephrons into native kidneys or into other sites in the organism,the repair of kidneys in situ with the use of stem cells, and the generation of histocompatible tissues with the use of nuclear transplantation. This new field combines principles of cell transplantation, materials science and engineering to construct biological substitutes that will restore the function of diseased and injured tissues This technology has great potential for use in renal replacement, but there are several safety issues common to the options. First, transformation of stem cells into cells with oncogenic potential can occur; harnessing stemcell proliferative potential could help to optimize the amount of tissue that is repaired, but proliferation could become neoplastic.25 Maintaining the functionality and viability of cells that are either injected or implanted into tissue-engineered devices, and the immunological issues associated with the use of nonautologous cells, are further obstacles. Delivering cells to the correct anatomical location and preventing them from migrating thereafter is also challenging.
7 Peritoneal dialysis Peritoneal dialysis now the most commonly practiced form of home dialysis is used to treat an estimated 250,000 individuals worldwide.1 Use of the therapy has always been strongly influenced by extrinsic factors such as government policy and clinician reimbursement. Although increasing overall, particularly in emerging economies, use of peritoneal dialysis is stable or decreasing in countries where more money is spent on health care but where different pressures apply. Changes in health-care trends present both opportunities and challenges to peritoneal dialysis. Growth is good for business, so a guaranteed increase in the use of the
8 therapy will ensure continued industrial and clinical investment and innovation. Peritoneal dialysis is the most common method of home dialysis and its relative simplicity is attractive in many settings; for example, use of the therapy enables and encourages patient autonomy and control, which is in keeping with the aspirations of self care in chronic disease management and translates into greater reported treatment satisfaction. Evidence also exists that in many health-care systems, peritoneal dialysis is less costly than in-centre haemodialysis. A recent cost benefit analysis of peritoneal dialysis in the UK by the National Institute of Clinical Excellence estimated that the country s National Health Service could make significant savings if the proportion of patients who commence renal replacement treatment with peritoneal dialysis was increased. This finding undoubtedly also applies to many other countries that do not currently take sufficient advantage of the therapy, such as the USA, where recent changes to the dialysis reimbursement system have been designed to encourage greater usage of home dialysis. In some countries, notably Hong Kong, Mexico and Thailand, high use of peritoneal dialysis in the context of a peritoneal dialysis-first policy has largely been a result of health economic arguments. However, these arguments are not universally applicable; in countries like India that have to import dialysis fluid and/or in those with very low labour costs, peritoneal dialysis may be more expensive than haemodialysis. Challenges of peritoneal dialysis Along with its own set of advantages as RRT, peritoneal dialysis has been ridden with several challenges. For example, given the high and increasing prevalence of obesity and metabolic syndrome in patients with CKD, a treatment that relies on regular intraperitoneal infusions of glucose (potentially resulting in hyperglycaemia and weight gain) must be viewed with caution. Increasing evidence indicates that diabetic patients with poor metabolic control who receive peritoneal dialysis have poorer survival than patients without diabetes who receive the therapy. Transient hyperglycaemia and progressive worsening of atherogenic lipid profiles has been shown to occur in nondiabetic patients on peritoneal dialysis and although increased BMI has been reported to have a protective effect in patients on haemodialysis, this is not the case in patients on peritoneal dialysis where increased BMI may be associated with worse outcomes. In addition, reports from Europe and the USA consistently suggest that older women, but not older men, with diabetes survive less well on peritoneal dialysis than on haemodialysis. Further research is required to understand the reason for this reduced survival (which might not be directly related to metabolic control) and for the sex-related difference. Possible explanations include underestimation of associated comorbidity, such as diastolic heart failure (which is poorly recognized in women) and/or insufficient social support for older women with diabetes. Another major challenge for increasing the utilization of peritoneal dialysis in an ageing and increasingly multimorbid population, is overcoming the accompanying barriers to independent self care. As discussed in detail below, these barriers are often multiple and complex and are as dependent on social and cultural factors as on clinical constraints. Little doubt exists, however, that these barriers are surmountable in many situations. The proportion of patients treated with home therapies varies considerably; in some Swedish dialysis units
9 approximately 40% of patients are treated at home (B. Rippe, personal communication) whereas in many dialysis units worldwide only in-centre treatment is available. The place of peritoneal dialysis in the environmental agenda has not yet been properly quantified. As mentioned earlier, this treatment modality is associated with a high use of consumables as well as with the manufacture and disposal of dialysate fluid and plastic containers. The industry has made efforts to improve the constituents of the containers (for example plasticizers) in order to improve drug stability and reduce wastage but heat sterilization and incineration generates greenhouse gases. Set against these disadvantages is the advantage of reduced travel for patients receiving dialysis at home, although this benefit will be ameliorated if these patients require outside assistance with their treatment Patient survival on peritoneal dialysis Over the past two decades, the survival of patients treated with peritoneal dialysis has steadily improved, both in absolute terms and in comparison to that of patients receiving haemodialysis. A randomized trial of peritoneal dialysis versus haemodialysis that is currently recruiting in China will add value to our understanding but is unlikely to influence the overall picture of survival on dialysis, which can be summarized as follows: firstly, the improvement in survival of patients on peritoneal dialysis over the past 20 years has occurred at a consistent rate in North America and Europe, and has out-stripped the improvement in survival seen in patients on haemodialysis and secondly, overall medium-term survival (3 5 years in most analyses) is now equivalent for peritoneal dialysis and haemodialysis. A couple of exceptions to these findings exist; for example, the Choices for Healthy Outcomes in Caring for End-stage Renal Disease (CHOICE) study reported survival patterns, such as better survival in patients with diabetes on peritoneal dialysis than on haemodialysis, that are wholly at odds with data from other studies. In addition, an analysis of data from the Australia and New
10 Zealand Dialysis and Transplant Registry (ANZDATA) found that overall patient survival was worse on peritoneal dialysis than on haemodialysis in a pattern not dissimilar to the findings of earlier analyses undertaken in the USA and in The Netherlands. Disproportionality of the peritoneal dialysis and haemodialysis survival curves has been described repeatedly, and as discussed above, tends to favour longer-term survival of older, female patients with diabetes who are on haemodialysis, although in the case of the ANZDATA registry study there was also an interaction with obesity, again favouring haemodialysis. Finally, the early survival benefit reported with peritoneal dialysis is most evident in those patients with the least comorbidity, and in at least one analysis could be attributed to increased mortality associated with the use of temporary lines in haemodialysis patients, which itself may be a surrogate for the quality of predialysis management and planning.
11 Renal transplantation Kidney transplantation an experimental, risky and very limited treatment option 50 years ago is now routine clinical practice in more than 80 countries. What was once limited to a few individuals in a small number of academic centers is routinely transforming lives in most high-income and medium-income countries. The largest numbers of kidney transplantations are performed in the USA, China, Brazil and India, whereas the greatest population-adjusted access to kidney transplantation occurs in Croatia, Portugal, Spain, Austria, the USA and Norway.1 Almost all countries, however, have rising waiting lists and donor organ availability meets only 10% of global needs. Barriers to the broader application of kidney transplantation include economic limitations, but the major restrictions on kidney transplantation rates are the shortage of donated organs and the number of trained medical workforces with the required expertise. The first successful kidney transplantation was carried out between identical twins in Between 1965 and 1980 patient survival after kidney transplantation
12 progressively increased towards 90% and graft survival rose to at least 60%. 30 years on, unsensitized recipients of first deceased or living donor kidney transplants can expect 1-year patient survival rates of 95% and transplant survival of at least 90%.2 Recent developments have also led to excellent results in ABO-incompatible recipients with low-titer ABO antibodies, and desensitization protocols and paired kidney exchange programs now afford real opportunities for individuals who have high titers of donor-specific anti-hla antibodies and were previously deemed unsuitable for transplantation. Kidney transplantation improves life expectancy and quality of life compared with maintenance dialysis. Transplantation, especially when it pre-empts dialysis, provides a mechanism both to expand access and reduce costs for the successful treatment of end-stage renal disease (ESRD). Developing countries have poor transplantation rates because of a combination of factors: low infrastructure levels; insufficient training; lack of legal frameworks to govern brain death; religious, cultural and social constraints; patient apprehension; physician bias; commercial incentives that favor dialysis, and geographical remoteness. Poor access to transplantation is therefore almost inevitable for most of the world s population Renal transplantation vs Dialysis: Kidney transplantation was associated with reduced risk of mortality and cardiovascular events as well as better quality of life than treatment with chronic dialysis. This is true for different dialysis modalities, for transplantation from both deceased and living donors and across countries with differing health care systems. It can be said kidney transplantation is the preferred modality of treatment for chronic kidney failure, and justifies current attempts to increase the number of patients worldwide who benefit from kidney transplantation by increasing rates of deceased and living kidney donation, expanding the pool of potential donors and recipients and reducing the likelihood that potentially viable organs are discarded. Immunosuppressive medications used in transplant recipients may cause anemia, hypertension, glucose intolerance and dyslipidemia. Despite this, transplantation was associated with significantly lower risk of cardiovascular events compared to treatment with dialysis. Although this finding might be partially because of selection of healthier patients for transplantation, results were similar in analyses restricted to dialysis patients who were active on the transplant waiting list which should minimize the effect of such bias. Although immunosuppressive medications can predispose to infection, transplantation is associated with reduced risk of hospitalization for infection emphasizing the high risk of sepsis associated with vascular and peritoneal access required to perform dialysis.
13 Pre-emptive kidney transplantation Pre-emptive kidney transplantation (PKT), which is carried out before starting either hemodialysis or chronic peritoneal dialysis, has been demonstrated to be the optimal treatment strategy for patients with advanced chronic kidney disease (CKD). PKT improves short-term and long-term patient survival and quality of life (including a shortening of the time taken to return to work) and reduces total medical and social costs. Moreover, use of PKT avoids most of the usual complications caused by renal replacement therapy, such as permanent vascular access for hemodialysis, peritoneal infections associated with chronic peritoneal dialysis and cardiovascular complications, such as sudden cardiac death and coronary lesions. However, although PKT is an ideal procedure for patients with CKD, its widespread use is thwarted by a shortage of living and deceased donors. The availability of donors also varies with a country s rules about organ retrieval and allocation, the difficulties in many countries of encouraging people to be living donors and the huge discrepancy between the size of waiting lists and the number of organs harvested from deceased donors. These problems can mean that patients spend long periods of time on transplantation waiting lists and are likely to receive a transplant from an extended- criteria donor. In PKT, living donor transplantation is easier than cadaveric transplantation, as the timing of surgery for a deceased donor transplantation depends on the rules for organ allocation in a particular transplantation network program. Although PKT is widely accepted as superior to other renal replacement therapies, no optimal time during the course of CKD has been recommended for this procedure. If a transplantation is carried out too early (that is, before the optimal time for renal replacement, which depends on various factors, including the cause of nephropathy and good control of blood pressure), it can induce premature loss of any remnant renal function, thereby decreasing the overall time until dialysis is required and increasing the complications caused by immunosuppression. However, early PKT does prevent CKD-associated cardiovascular morbidity and mortality. Conversely, transplantation carried out too late exposes recipients to the severe complications of end-stage CKD that are sometimes life-threatening, such as fluid overload, hyperkalemia and emergency hemodialysis by catheter before surgery. Thus, PKT seems to be an ideal procedure, but the optimal timing of the procedure and its effects on patient and graft survival remain undetermined.
Chapter 2 End-Stage Renal Disease: Scope and Trends
Chapter 2 End-Stage Renal Disease: Scope and Trends Chapter 2 End-Stage Renal Disease: Scope and Trends END-STAGE RENAL DISEASE DEFINED The primary functions of the kidney are to remove waste products
More informationUnited States Renal Data System (USRDS) International Data Collection Form
United States Renal Data System (USRDS) International Data Collection Form This form is designed to solicit information on the population of End-Stage Renal Disease (ESRD) patients in your country who
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationHEALTHYSTART TRAINING MANUAL. Living well with Kidney Disease
HEALTHYSTART TRAINING MANUAL Living well with Kidney Disease KIDNEY DISEASE CAN AFFECT ANYONE! 1 HEALTHYSTART PROGRAMME HEALTHYSTART is a lifestyle management programme to assist you to remain healthy
More informationJadranka Buturović-Ponikvar Department of Nephrology, University Medical Center, Ljubljana, Slovenia
Jadranka Buturović-Ponikvar Department of Nephrology, University Medical Center, Ljubljana, Slovenia Hemodialysis or kidney transplantation what is better? Jadranka Buturović-Ponikvar Department of Nephrology,
More informationEnd-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology
End-Stage Renal Disease Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology ESRD : Life with renal replacement therapy CASE: 18 month old male with HUS develops ESRD PD complicated
More information39th SESSION OF THE SUBCOMMITTEE ON PLANNING AND PROGRAMMING OF THE EXECUTIVE COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 39th SESSION OF THE SUBCOMMITTEE ON PLANNING AND PROGRAMMING OF THE EXECUTIVE COMMITTEE Washington, D.C., USA, 16-18 March 2005 Provisional Agenda
More informationPatient Education Programme. Kidney Options Guiding you when kidneys fail
Patient Education Programme Kidney Options Guiding you when kidneys fail About the kidneys What do healthy kidneys do? Your two kidneys work more than you realise. The kidneys remove excess body water
More information. Time to transplant listing is dependent on. . In 2003, 9.1% of all prevalent transplant. . Patients with diabetes mellitus are less
Chapter 5: Joint Analyses with UK Transplant in England and Wales; Access to the Renal Transplant Waiting List, Time to Listing, Diabetic Access to Transplantation and the Influence of Social Deprivation
More informationRenal Replacement Therapy in Acute Renal Failure
CHAPTER 82 Renal Replacement Therapy in Acute Renal Failure R. Deshpande Introduction Acute renal failure (ARF) is defined as an abrupt decrease in renal function sufficient to result in retention of nitrogenous
More informationChronic Kidney Disease. Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital
Chronic Kidney Disease Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital Health Seminar Series Date 12 May 2013 Objectives Normal functioning of Kidneys. Risk factors to
More informationCHAPTER 9. End Stage Kidney Disease in Aotearoa/New Zealand
CHAPTER 9 End Stage Kidney Disease in Aotearoa/New Zealand ANZDATA gratefully acknowledges the patients and their families and the clinicians who provided data, and the contributions of the Aotearoa/New
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationKidney Decisions Aid
Kidney Decisions Aid A G U I D E F O R P E O P L E W H O H A V E, O R K N O W S O M E O N E, W I T H C H R O N I C K I D N E Y D I S E A S E, A N D T O A I D I N T H E D E C I S I O N A B O U T W H I C
More informationYour Kidney Health. Your Choices. Chronic Kidney Disease
Your Kidney Health Your Choices Your doctor may have told you that you have chronic kidney disease (CKD or advanced kidney disease; or, you may be in kidney failure, and may have to make a decision about
More informationPD In Acute Kidney Injury. February 7 th -9 th, 2013
PD In Acute Kidney Injury February 7 th -9 th, 2013 Objectives PD as a viable initial therapy PD in AKI PD versus dhd PD versus CVVHD Why not PD first PD for AKI Early days (1970 s) PD was the option of
More informationCHAPTER 12 END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES OF AUSTRALIA AND NEW ZEALAND. Stephen McDonald. Matthew Jose. Kylie Hurst INDIGENOUS 12-1
ANZDATA Registry 213 Report INDIGENOUS END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES OF AUSTRALIA AND NEW ZEALAND CHAPTER 12 Stephen McDonald Matthew Jose Kylie Hurst 213 Annual Report - 36th Edition
More informationKidney Patients with Chronic Kidney Disease
Cheshire and Merseyside Kidney Care Services Renal Replacement Therapy Options for Kidney Patients with Chronic Kidney Disease Stage 5 Renal Replacement Therapy Options for Kidney Patients with Chronic
More informationEnd Stage Kidney Disease Among Indigenous Peoples of Australia and New Zealand
Chapter 12 End Stage Kidney Disease Among Indigenous Peoples of and New Zealand 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Introduction In this chapter, rates of end-stage kidney disease
More informationChronic Kidney Disease. Basics of CKD Terms Diagnosis Management
Chronic Kidney Disease Basics of CKD Terms Diagnosis Management Review the prevalence of chronic kidney disease (CKD) Review how CKD develops Review populations at risk for CKD Review CKD diagnosis Objectives
More informationChapter 12. End Stage Kidney Disease in Indigenous Peoples of Australia and Aotearoa/New Zealand. ANZDATA Registry 39th Annual Report
Chapter 12 End Stage Kidney Disease in Indigenous Peoples of and Aotearoa/ 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Introduction In this chapter, the rates and practice patterns for end-stage
More informationChapter six Outcomes: hospitalization & mortality. There is an element of death in life, and I am astonished
INTRODUCTION 1 OVERALL HOSPITALIZATION & MORTALITY 1 hospital admissions & days, by primary diagnosis & patient vintage five-year survival mortality rates, by patient vintage expected remaining lifetimes
More informationDisparities in Transplantation Caution: Life is not fair.
Disparities in Transplantation Caution: Life is not fair. Tuesday October 30 th 2018 Caroline Rochon, MD, FACS Surgical Director, Kidney Transplant Program Hartford Hospital, Connecticut Outline Differences
More informationECMO & Renal Failure Epidemeology Renal failure & effect on out come
ECMO Induced Renal Issues Transient renal dysfunction Improvement in renal function ECMO & Renal Failure Epidemeology Renal failure & effect on out come With or Without RRT Renal replacement Therapy Utilizes
More informationChapter Five Clinical indicators & preventive health
Chapter Five Clinical indicators & preventive health The painter who draws merely by practice and by eye, without any reason, is like a mirror which copies every thing placed in front of it without being
More informationCHAPTER 4 METHOD AND LOCATION OF DIALYSIS. Nancy Briggs Kylie Hurst Stephen McDonald Annual Report 35th Edition
CHAPTER 4 METHOD AND LOCATION OF DIALYSIS Nancy Briggs Kylie Hurst Stephen McDonald 212 Annual Report 35th Edition METHOD AND LOCATION OF DIALYSIS ANZDATA Registry 212 Report AUSTRALIA Figure 4.1 Aust
More informationDrug Use in Dialysis
(Last Updated: 08/22/2018) Created by: Socco, Samantha Drug Use in Dialysis Drambarean, B. (2017). Drug Use in Dialysis. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago. DIALYSIS
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationRini Purwanti Sekretaris PD IPDI Jatim
Kidney Emergency Rini Purwanti Sekretaris PD IPDI Jatim overview The kidneys are a pair of small ( about the size of your fist-sized ), bean shaped organs that lie on either side of your spine, located
More informationTransplant Options for Patients: Choices and Consequences. Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital
Transplant Options for Patients: Choices and Consequences Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital BC Kidney Days October 6 th 2017 Non contributory Conflict of
More informationOptions in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology
Options in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology CKD Classification Stage Description GFR (ml/min/1.73.m2) 1 Kidney
More informationFor more information about how to cite these materials visit
Author(s): Silas P. Norman, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationDiabetes and Kidney Disease: Time to Act. Your Guide to Diabetes and Kidney Disease
Diabetes and Kidney Disease: Time to Act Your Guide to Diabetes and Kidney Disease Diabetes is fast becoming a world epidemic Diabetes is reaching epidemic proportions worldwide. Every year more people
More informationTRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA
& TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA 2002-2008 Halima Resić* 1, Enisa Mešić 2 1 Clinic for Hemodialysis, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia
More information2015 Investor Conference
2015 Investor Conference ACCELERATING PROFITABLE GROWTH Jill Schaaf President, Renal Care Teeramanas Tanaekakarapong, ESRD Patient, Bangkok, Thailand Becoming The Global Leader In Renal Care Our Global
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in ESRD patients, with atherosclerotic heart disease and congestive heart
More informationStarting with Home Dialysis. Budapest Nephrology School 2016 Ágnes Haris MD, PhD, Kálmán Polner MD St. Margit Hospital, Budapest
Starting with Home Dialysis Budapest Nephrology School 2016 Ágnes Haris MD, PhD, Kálmán Polner MD St. Margit Hospital, Budapest Major concept of the RRT modality selection Hemodialysis Peritoneal dialysis
More informationNew global report highlights silent epidemic of kidney disease and neglect of treatment and prevention in all countries
New global report highlights silent epidemic of kidney disease and neglect of treatment and prevention in all countries An estimated 1 in 10 people worldwide have chronic kidney disease **Embargo: 18:00H
More informationAcute renal failure ARF
Acute renal failure ARF Definition ARF is a clinical syndrome characterized by an abrupt decline in GFR and the accumulation of nitrogenous waste (BUN & creatinine). The decrease in GFR occurs relatively
More informationSpecialised renal services and QIPP
Specialised renal services and QIPP Contents 1. Executive summary 2. Background 2.1 QIPP 2.2 Specialised renal services 3. Main themes 3.1 Need 3.2 Diagnosis 3.3 Commissioning 3.4 Treatment 3.5 Care 4.
More information5. Comparison of continuous cyclic peritoneal dialysis (CCPD) with CAPD in treatment for patients with ESRD.
Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews MacLeod A, Grant A, Donaldson C, Khan I, Campbell M, Daly C, Lawrence P, Wallace S, Vale L, Cody
More informationGlobal End Stage Renal Disease (ESRD) Market With Focus on Dialysis Market ( Edition) July 2017
Global End Stage Renal Disease (ESRD) Market With Focus on Dialysis Market (2017-2021 Edition) July 2017 Scope of the Report Global End Stage Renal Disease Market The report titled Global End Stage Renal
More informationRENAL FAILURE IN ICU. Jo-Ann Vosloo Department Critical Care SBAH
RENAL FAILURE IN ICU Jo-Ann Vosloo Department Critical Care SBAH DEFINITION: RIFLE criteria Criteria for initiation of RRT Modes of RRT (options) CRRT = continuous renal replacement therapy SCUF : Ultra-filtration
More informationManagement of End Stage Renal Disease-Bangladesh Perspective
Send Orders for Reprints to reprints@benthamscience.net 108 The Open Urology & Nephrology Journal, 2014, 7, 108-112 Management of End Stage Renal Disease-Bangladesh Perspective Harun Ur Rashid * Open Access
More informationKidney Disease Treatment Options
Page 1 Fact sheet The kidneys play a number of important roles in your body such as: extracting excess water to make urine (wee) controlling your blood pressure filtering waste products and toxins from
More informationAcute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis
Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? A common condition in ICU patients Associated with high mortality and morbidity Renal Replacement Therapy (RRT) is the cornerstone
More informationRENAL & HEMATOLOGY EMERGENCIES JEFF SIMONS B.S. F-PC
RENAL & HEMATOLOGY EMERGENCIES JEFF SIMONS B.S. F-PC GOALS Overview of renal system anatomy / physiology Discuss common medical / trauma renal issues Identify associated assessment keys GOALS Introduction
More informationObjectives. Peritoneal Dialysis vs. Hemodialysis 02/27/2018. Peritoneal Dialysis Prescription and Adequacy Monitoring
Peritoneal Dialysis Prescription and Adequacy Monitoring Christine B. Sethna, MD, EdM Division Director, Pediatric Nephrology Cohen Children s Medical Center Associate Professor Hofstra Northwell School
More informationmorbidity & mortality
morbidity & mortality esrd introduction of ESRD treatment. We examine these concerns throughout the ADR, particularly in Chapter One. This year we focus on infectious complications, especially those related
More informationBLAZING TRAILS IN TRANSPLANTATION. Danielle Fritze, MD
BLAZING TRAILS IN TRANSPLANTATION Danielle Fritze, MD BETTER TODAY THAN YESTERDAY BETTER TOMORROW THAN TODAY. Jim Harbaugh,via Twitter (and others) Transplant s Joseph Murray Legacy The Herrick Twins NPR,
More informationTreatment choices for someone with Stage 5 kidney disease are:
Information for patients about advanced kidney disease Dialysis and non-dialysis treatments DOCUMENT PREPARED FOR This information is to help you understand some key issues about dialysis; it is designed
More informationYOUR KIDNEYS AREN T WORKING PROPERLY.
When you re born, everything works perfectly. Then something goes wrong and you ask: YOUR KIDNEYS AREN T WORKING PROPERLY. What does this mean? How can you stay healthy? HOW DO I DEAL WITH THIS? WHAT ROLE
More informationNew Zealand. Dialysis and Transplantation Audit
New Zealand Dialysis and Transplantation Audit Report for New Zealand Nephrology Services on behalf of the National Renal Advisory Board Grant Pidgeon Standards and Audit Subcommittee July 2012 Establishment
More informationCOST MANAGEMENT: HOW CONVENIENT IS HOME HEMODIALYSIS?
Unione Europea Bando "Aiuti a Sostegno dei Cluster Tecnologici Regionali " COST MANAGEMENT: HOW CONVENIENT IS HOME HEMODIALYSIS? Maria Pia dell Oglio, Clinical Pathologist, Ph.D BACKGROUND Renal replacement
More informationCHRONIC KIDNEY FAILURE
CHRONIC KIDNEY FAILURE Overview Chronic kidney disease, also called chronic kidney failure, describes the gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood,
More informationRenal Replacement Therapies
Renal Replacement Therapies M I H Á L Y T A P O L Y A I, M D, F A S N, F A C P A s s o c i a t e P r o f e s s o r D e p a r t m e n t o f N e p h r o l o g y L o u i s i a n a S t a t e U n i v e r s
More informationAcceptance onto dialysis guidelines: St George Hospital
Acceptance onto dialysis guidelines: St George Hospital The following information is a guideline to support clinicians in decision making regarding acceptance onto dialysis. A review of international guidelines
More informationRenal replacement therapy in Pediatric Acute Kidney Injury
Renal replacement therapy in Pediatric Acute Kidney Injury ASCIM 2014 Dr Adrian Plunkett Consultant Paediatric Intensivist Birmingham Children s Hospital, UK Aims of the presentation Important topic: AKI
More informationWendy Washington & Anne Graham. Nephrology Nurse Practitioners
Wendy Washington & Anne Graham Nephrology Nurse Practitioners Eight major risk factors for CKD Diabetes High blood pressure Age over 60 years Smoking Obesity Family history of kidney disease Aboriginal
More informationNational Kidney and Urologic Diseases Information Clearinghouse (NKUDIC)
National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC) A service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) Kidney
More informationEvidence-based practice in nephrology : Meta-analysis
Evidence-based practice in nephrology : Meta-analysis Paweena Susantitaphong, MD,Ph.D 1-3 1 Associate Professor, Division of Nephrology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn
More informationHome Dialysis. Peritoneal Dialysis. Home Hemodialysis
Home Dialysis The information provided is not intended to be a substitute for professional medical advice. A licensed healthcare professional should be consulted for diagnosis and treatment of any and
More informationIt is important upfront to realize and believe that, like many adults,
Kids With Kidney Disease Can Realize Their Dreams and Live Long, Normal, Productive Lives By Gordon Lore It is important upfront to realize and believe that, like many adults, children with kidney failure
More informationRenal Transplantation: Allocation challenges and changes. Renal Transplantation. The Numbers 1/13/2014
Renal Transplantation: Allocation challenges and changes Mark R. Wakefield, M.D., F.A.C.S. Associate Professor of Surgery/Urology Director Renal Transplantation Renal Transplantation Objectives: Understand
More informationLiving Donor Paired Exchange (LDPE)
Living Donor Paired Exchange (LDPE) Why do we need Living Donation? 3,796 patients waiting for an organ transplant 2,679 (71%) waiting for a kidney transplant 249 people died while waiting for an organ
More informationAppendix C: Renal Services Described for Non-physicians
Appendix C: Renal Services Described for Non-physicians (Reproduced from the third edition of the Renal Association Standards document, August 2002.) This appendix provides information on the issues discussed
More informationKIDNEY EXCHANGE PROGRAMMES IN EUROPE. Position Paper of the. European Committee on Organ Transplantation (CD-P-TO) of the Council of Europe
KIDNEY EXCHANGE PROGRAMMES IN EUROPE Position Paper of the European Committee on Organ Transplantation (CD-P-TO) of the Council of Europe 1. Introduction Approximately one in a thousand European citizens
More informationRationale for renal replacement therapy in ICU: indications, approaches and outcomes. Richard Beale
Rationale for renal replacement therapy in ICU: indications, approaches and outcomes Richard Beale RIFLE classification (ADQI group) 2004 Outcome AKIN classification Definition: Abrupt (within 48 hrs)
More informationKIDNEY FAILURE TREATMENT OPTIONS Choosing What s Best For You
KIDNEY FAILURE TREATMENT OPTIONS Choosing What s Best For You What Kidneys Do The kidneys are a pair of bean shaped organs located below your ribcage near the middle of your back. Kidneys play a vital
More informationDifference in practical dialysis therapy between East Asia and US/EU
Difference in practical dialysis therapy between East Asia and US/EU Jer-Ming Chang. M.D., Ph.D. 1 Professor, Attending physician, Kaohsiung Medical University Hospital; 2 Secretary General, Taiwan Society
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers HOW
More informationYou can sleep while I dialyze
You can sleep while I dialyze Nocturnal Peritoneal Dialysis Dr. Suneet Singh Medical Director, PD, VGH Division of Nephrology University of British Columbia Acknowledgements Melissa Etheridge You can sleep
More informationPOSITION STATEMENT ON THE PROPOSAL FOR A GLOBAL KIDNEY EXCHANGE
POSITION STATEMENT ON THE PROPOSAL FOR A GLOBAL KIDNEY EXCHANGE as adopted by the WHO Task Force on Donation and Transplantation of Human Organs and Tissues The Task Force on Donation and Transplantation
More informationChapter 8: Cardiovascular Disease in Patients with ESRD
Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)
More informationBack to dialysis after graft failure: Transplantectomy or not? Stop immunosuppression?
Back to dialysis after graft failure: Transplantectomy or not? Stop immunosuppression? Laurent WEEKERS CHU SartTilman Layout Introduction Epidemiology A note of caution on causality and bias Patient survival
More informationPALLIATIVE CARE FOR PATIENTS AND FAMILIES LIVING WITH CKD AND ESRD
PALLIATIVE CARE FOR PATIENTS AND FAMILIES LIVING WITH CKD AND ESRD Karen Solcher, MSN, APRN, NP-C, CNN-NP Nephrology Nurse Practitioner Stormont-Vail Health DISCLAIMER Adult population Clinical practice
More informationRenal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology
Renal Disease and PK/PD Anjay Rastogi MD PhD Division of Nephrology Drugs and Kidneys Kidney is one of the major organ of drug elimination from the human body Renal disease and dialysis alters the pharmacokinetics
More informationChristopher R. Blagg. Turkish Society of Nephrology
Home Hemodialysis Christopher R. Blagg Turkish Society of Nephrology 2010 Kolff s 1961 tribute to Scribner a drawing by Mervin La Rue Kolff: Undoubtedly, we all want our artificial kidneys at home, and
More informationDialyzing challenging patients: Patients with hepato-renal conditions
Dialyzing challenging patients: Patients with hepato-renal conditions Nidyanandh Vadivel MD Medical Director for Living kidney Donor and Pancreas Transplant Programs Swedish Organ Transplant, Seattle Acute
More informationREIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange
REIMBURSEMENT AND ITS IMPACT ON YOUR DIALYSIS PROGRAM Tony Messana Executive Director Renal Services St. Joseph Hospital - Orange Agenda History of the Medicare ESRD Program Cost of Care for ESRD Patients
More informationEpidemiology of kidney diseases in children
Epidemiology of kidney diseases in children Dr Lesley Rees Gt Ormond St Hospital for Children, London, UK September 2015 Definition of Epidemiology The patterns, causes, and effects of health and diseases
More informationProtocol Version 2.0 Synopsis
Protocol Version 2.0 Synopsis Title Short Title Plasma exchange and glucocorticoid dosing in anti-neutrophil cytoplasm antibody associated vasculitis: a randomized controlled trial. PEXIVAS PEXIVAS Clinical
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationChapter 9: Cardiovascular Disease in Patients With ESRD
Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions
More informationKIDNEY TRANSPLANTATION: THE BIG PICTURE
KIDNEY TRANSPLANTATION: THE BIG PICTURE Alden Doyle, MD, MS, MPH Aim To provide practical overview of the how kidney transplantation works and why it is an attractive option for patients with advanced
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationBurden of end-stage renal disease
Summary of Indigenous health: End-stage renal disease Neil Thomson and Sasha Stumpers Australian Indigenous HealthInfoNet, Edith Cowan University www.healthinfonet.ecu.edu.au This summary of end-stage
More informationUtopia Health Career Center
Utopia Health Career Center Magda Castaneda RN, BSN, CNN, HTC Coordinator / Instructor BONENT Approved Program Florida Board of Nursing CE Provider # 50-16333 Property of Utopia Health Career Center, LLC.
More informationDefinitions. You & Your New Transplant ` 38
Definitions Acute Short, relatively severe Analgesic Pain medicine Anemia A low number of red blood cells Anesthetic Medication that dulls sensation in order to reduce pain Acute Tubular Necrosis (ATN)
More informationFundamentals of DIALYSIS
Fundamentals of DIALYSIS Knowing Your Kidneys Healthy Kidneys are the body s cleaning crew These are twin bean shaped organs, of the size of fist They make up a filter system for the blood & reabsorb almost
More informationUtopia Health Career Center, LLC. Do not distribute without permission.
Introduction What is dialysis and a brief history. What laws govern dialysis treatments. How to ensure high quality care for patients. How to behave in a professional way. How to become certified. We don
More informationGeriatric Nutritional Risk Index, home hemodialysis outcomes 131
Subject Index Aksys PHD system 113 Anemia, home outcomes 111, 172, 173 Automated peritoneal dialysis dialysis comparison 17, 18 selection factors 18, 19 telemedicine system 19 21 Blood pressure -peritoneal
More informationArches National Park, Utah. hospitalization
Arches National Park, Utah 237 212 USRDS annual data report 2volume 238 24 overall 242 re 244 admission rates by interdialytic interval 246 summary Remote from universal nature and living by complicated
More informationKeeping your options open. Transplant In Center Hemodialysis Home Hemodialysis Peritoneal dialysis No dialysis
Keeping your options open Transplant In Center Hemodialysis Home Hemodialysis Peritoneal dialysis No dialysis Survival With/Without Transplant % of Transplants 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% Recipient
More informationWHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington
WHEN (AND WHEN NOT) TO START DIALYSIS Shahid Chandna, Ken Farrington Changing Perspectives Beta blockers 1980s Contraindicated in heart failure Now mainstay of therapy HRT 1990s must Now only if you have
More informationWaiting for a Kidney. Objectives
Waiting for a Kidney Department of Urologic Sciences Grand Rounds William Gourlay Christopher Nguan April 25, 2007 Objectives 1. review the waiting times for deceased-donor kidney transplants in BC and
More informationNHSBT Board July Update on UK Living Kidney Sharing Scheme
1. Status Public 2. Executive Summary NHSBT Board July 27 2017 Update on UK Living Kidney Sharing Scheme This paper provides an update on activity and plans for the UK Living Kidney Sharing Scheme (UKLKSS),
More information50 years Anniversary of First Kidney Transplant at Manchester Royal Infirmary
50 years Anniversary of First Kidney Transplant at Manchester Royal Infirmary Consultant Transplant Surgeon Clinical Lead for Manchester /North west Paediatric Transplantation & Abdominal National Organ
More information2017 USRDS ANNUAL DATA REPORT KIDNEY DISEASE IN THE UNITED STATES S611
Healthy People 2020 In this chapter, we examine data for 11 Healthy People 2020 (HP2020) objectives 10 for CKD and one for diabetes spanning 20 total indicators for which the USRDS serves as the official
More information